Innate Pharma Financial Flexibility Index
Innate Pharma financial flexibility index. Innate Pharma (IPHA) has a Financial Flexibility Index of -0.28x as of March 2026. Free cash flow of $-23.31 Million (operating CF $-23.40 Million minus capex $85.05K) represents 0% of total liabilities ($84.39 Million). See Innate Pharma (IPHA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Innate Pharma (2005–2025)
Financial flexibility index of Innate Pharma from 2005 to 2025. Historical Financial Flexibility Index trend for Innate Pharma across 21 annual periods. Check IPHA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Innate Pharma Financial Flexibility Index by Year (2005–2025)
Innate Pharma financial flexibility index by year from 2005 to 2025. Year-by-year free cash flow to debt coverage for Innate Pharma. For the full cash flow conversion analysis, see Innate Pharma cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.60x | $-50.54 Million | $-50.67 Million | $84.39 Million | ▼ -841.1% |
| 2024 | -0.06x | $-6.50 Million | $-6.90 Million | $102.22 Million | ▲ +72.1% |
| 2023 | -0.23x | $-30.21 Million | $-32.56 Million | $132.29 Million | ▼ -94.6% |
| 2022 | -0.12x | $-18.03 Million | $-19.15 Million | $153.71 Million | ▲ +67.1% |
| 2021 | -0.36x | $-57.13 Million | $-58.46 Million | $160.06 Million | ▼ -33.4% |
| 2020 | -0.27x | $-40.52 Million | $-51.81 Million | $151.45 Million | ▼ -149.1% |
| 2019 | 0.55x | $100.33 Million | $34.92 Million | $183.94 Million | ▲ +598.0% |
| 2018 | -0.11x | $-31.10 Million | $-32.53 Million | $283.98 Million | ▲ +55.9% |
| 2017 | -0.25x | $-42.03 Million | $-48.06 Million | $169.07 Million | ▼ -76.9% |
| 2016 | -0.14x | $-27.46 Million | $-36.85 Million | $195.41 Million | ▼ -115.3% |
| 2015 | 0.92x | $215.31 Million | $207.91 Million | $233.89 Million | ▲ +193.6% |
| 2014 | -0.98x | $-15.79 Million | $-18.13 Million | $16.06 Million | ▼ -45.5% |
| 2013 | -0.68x | $-10.53 Million | $-10.97 Million | $15.60 Million | ▼ -82.0% |
| 2012 | -0.37x | $-9.25 Million | $-10.47 Million | $24.93 Million | ▼ -193.4% |
| 2011 | 0.40x | $13.31 Million | $12.99 Million | $33.48 Million | ▲ +144.2% |
| 2010 | -0.90x | $-13.04 Million | $-13.45 Million | $14.49 Million | ▼ -183.6% |
| 2009 | -0.32x | $-5.42 Million | $-5.94 Million | $17.10 Million | ▲ +51.8% |
| 2008 | -0.66x | $-12.84 Million | $-14.74 Million | $19.52 Million | ▼ -11.6% |
| 2007 | -0.59x | $-7.99 Million | $-9.28 Million | $13.55 Million | ▼ -783.1% |
| 2006 | 0.09x | $1.11 Million | $360.00K | $12.89 Million | ▲ +105.7% |
| 2005 | -1.52x | $-7.14 Million | $-7.25 Million | $4.70 Million | — |